Spontaneous and Treatment-Related Changes of Serum Calcitonin in Medullary Thyroid Cancer: Long-Term Experience in a Patient With Multiple Endocrine Neoplasia Type 2B
Source : https://pubmed.ncbi.nlm.nih.gov/38709988/
This case of MEN2B medullary thyroid cancer with long-term survival presents how the effectiveness of different treatment modalities can be estimated using log-transformed calcitonin levels. Furthermore, our experience supports the...
The best treatment response was observed with selpercatinib, which was associated with an initial large drop followed by a decreasing calcitonin trajectory over 514 days without any major adverse events.
Patient With Mediastinal Carcinoma of Unknown Primary With RET Fusion Achieves Durable Response With RET Inhibition
Source : https://pubmed.ncbi.nlm.nih.gov/38696710/
Selective RET inhibitors have shown promise in thyroid cancer (TC) and nonsmall cell lung cancer (NSCLC) harboring RET fusions on next-generation sequencing (NGS), although rarity of the rearrangement has led...
The patient demonstrated stable reduction of the mediastinal mass for >15 months with RET inhibition therapy despite several treatment interruptions.
Precision Nanomedicine to Treat Non-Small Cell Lung Cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38604287/
Lung cancer is a major cause of death worldwide, being often detected at a later stage due to the non-appearance of early symptoms. Therefore, specificity of the treatment is of...
The integration of theranostic cargos in the nanoparticle would allow diagnosis as well as treatment by targeting the site of disease progression.
Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy
Source : https://pubmed.ncbi.nlm.nih.gov/38651727/
We identified molecular alterations and immune-related features that distinguish wtRET from mutRET MTC. While RET mutation drives MTC in the absence of other alterations, we showed that wtRET MTC frequently...
These findings may indicate a potential basis for MAPK-targeted therapy, possibly in combination with oncology immune-oncology agents for selected patients with wild-type RET medullary thyroid cancer.
Oncogene-Driven Non-Small Cell Lung Cancers in Patients With a History of Smoking Lack Smoking-Induced Mutations
Source : https://pubmed.ncbi.nlm.nih.gov/38587551/
Non-small cell lung cancers (NSCLCs) in non-smokers are mostly driven by mutations in the oncogenes EGFR, ERBB2, and MET and fusions involving ALK and RET. In addition to occurring in...
Although the genomic landscape is similar between NSRO-driven NSCLC in smokers and nonsmokers, smoking still affects the tumor phenotype independently of genomic alterations.